Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD22 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD22 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD22 Products |
| Gene Delivery | CD22 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD22 Products |
| Benchmark Ab | Anti-CD22 (Sequence of Inotuzumab) Recombinant positive control. |
View CD22 Products |
| Validator | CD22 siRNA Set For knockdown verification. |
View CD22 Products |
| Related Target A | CD19 Synergistic pathway for dual-targeting CAR-T therapies. |
View CD19 Products |
| Related Target B | CD79b Alternative B-cell ADC target for combination regimens. |
View CD79b Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Rapid ADC Internalization Screening | HEK293 Expressed (Native Glycosylation) ECD-Fc for accurate endocytosis assays |
| CAR-T Target Density Validation | Stable cell lines via lentivirus delivery for precise flow cytometry calibration |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD22 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD22 therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs and CAR-T therapies. As first-generation therapies like inotuzumab ozogamicin reach the clinic, the next wave of R&D is targeting relapsed/refractory settings, particularly post-CD19 relapse, using dual-targeting CAR-Ts and next-generation payload ADCs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Pfizer, AstraZeneca | ALL, NHL | Internalization Assay (Need high-purity ECD-Fc) |
| CAR-T | Novartis, Stanford Medicine | Relapsed/Refractory ALL | Binding/Cytotoxicity (Need Sequence Verified Proteins) |
| Immunotoxin | AstraZeneca (Lumoxiti) | Hairy Cell Leukemia | Selectivity Assay (Need Homolog Panels) |